NYSE ARCA | ETF
The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index.
The underlying index was composed of common stocks ofU. S. biotechnology and genome companies.
These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc.
It is non-diversified.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| NTRA | Natera Inc | Healthcare | Diagnostics & Research | 5.74% |
| NBIX | Neurocrine Biosciences Inc | Healthcare | Drug Manufacturers - Specialty & Generic | 5.59% |
| VRTX | Vertex Pharmaceuticals Inc | Healthcare | Biotechnology | 4.85% |
| GILD | Gilead Sciences Inc | Healthcare | Drug Manufacturers - General | 4.85% |
| IMGN | ImmunoGen Inc | Healthcare | Biotechnology | 4.78% |
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 4.75% |
| UTHR | United Therapeutics Corporation | Healthcare | Drug Manufacturers - Specialty & Generic | 4.75% |
| ILMN | Illumina Inc | Healthcare | Diagnostics & Research | 4.58% |
| ALNY | Alnylam Pharmaceuticals Inc | Healthcare | Biotechnology | 4.56% |
| BIIB | Biogen Inc | Healthcare | Drug Manufacturers - General | 4.55% |
| REGN | Regeneron Pharmaceuticals Inc | Healthcare | Biotechnology | 4.17% |
| PTGX | Protagonist Therapeutics Inc | Healthcare | Biotechnology | 3.76% |
| AXSM | Axsome Therapeutics Inc | Healthcare | Biotechnology | 3.73% |
| BCRX | BioCryst Pharmaceuticals Inc | Healthcare | Drug Manufacturers - Specialty & Generic | 3.60% |
| HALO | Halozyme Therapeutics Inc | Healthcare | Biotechnology | 3.51% |
| TGTX | TG Therapeutics Inc | Healthcare | Biotechnology | 3.48% |
| CPRX | Catalyst Pharmaceuticals Inc | Healthcare | Biotechnology | 3.29% |
| BPMC | Blueprint Medicines Corp | Healthcare | Biotechnology | 3.25% |
| QGEN | Qiagen NV | Healthcare | Diagnostics & Research | 3.19% |
| EXAS | EXACT Sciences Corporation | Healthcare | Diagnostics & Research | 3.17% |